Hana Klamová

2.8k total citations
88 papers, 1.0k citations indexed

About

Hana Klamová is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Hana Klamová has authored 88 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Hematology, 47 papers in Genetics and 34 papers in Molecular Biology. Recurrent topics in Hana Klamová's work include Chronic Myeloid Leukemia Treatments (55 papers), Chronic Lymphocytic Leukemia Research (42 papers) and Acute Myeloid Leukemia Research (18 papers). Hana Klamová is often cited by papers focused on Chronic Myeloid Leukemia Treatments (55 papers), Chronic Lymphocytic Leukemia Research (42 papers) and Acute Myeloid Leukemia Research (18 papers). Hana Klamová collaborates with scholars based in Czechia, Italy and Poland. Hana Klamová's co-authors include Jana Moravcová, Kateřina Machová Poláková, Tomáš Stopka, Hana Bruchova, R Brdička, Markéta Žáčková, Karel Smetana, Pavel Burda, Marek Trněný and Zbyněk Hrkal and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

Hana Klamová

80 papers receiving 990 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hana Klamová Czechia 18 589 443 374 163 140 88 1.0k
Traudl Henn Austria 14 492 0.8× 426 1.0× 303 0.8× 64 0.4× 117 0.8× 21 1.0k
Jeffrey A. Durocher United States 6 299 0.5× 529 1.2× 303 0.8× 67 0.4× 133 0.9× 12 808
Yasuhiko Kamikubo Japan 16 448 0.8× 656 1.5× 177 0.5× 118 0.7× 17 0.1× 43 1.0k
Stéphanie Salesse France 16 222 0.4× 326 0.7× 133 0.4× 118 0.7× 54 0.4× 25 695
Kazuhiro Maki Japan 16 443 0.8× 610 1.4× 130 0.3× 78 0.5× 20 0.1× 37 898
Haruna Naito Japan 8 287 0.5× 277 0.6× 211 0.6× 61 0.4× 149 1.1× 16 583
Crescenzio Francesco Minervini Italy 18 228 0.4× 385 0.9× 187 0.5× 163 1.0× 17 0.1× 56 761
ID Dube Canada 13 434 0.7× 347 0.8× 225 0.6× 33 0.2× 41 0.3× 25 845
Jeffrey R. Shearstone United States 15 145 0.2× 644 1.5× 139 0.4× 108 0.7× 39 0.3× 27 1.0k
Elenoe C. Smith United States 10 319 0.5× 1.1k 2.4× 480 1.3× 65 0.4× 16 0.1× 16 1.4k

Countries citing papers authored by Hana Klamová

Since Specialization
Citations

This map shows the geographic impact of Hana Klamová's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hana Klamová with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hana Klamová more than expected).

Fields of papers citing papers by Hana Klamová

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hana Klamová. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hana Klamová. The network helps show where Hana Klamová may publish in the future.

Co-authorship network of co-authors of Hana Klamová

This figure shows the co-authorship network connecting the top 25 collaborators of Hana Klamová. A scholar is included among the top collaborators of Hana Klamová based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hana Klamová. Hana Klamová is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Žáčková, Daniela, Hana Klamová, Edgar Faber, et al.. (2024). Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data. Cancer Medicine. 13(17). e70158–e70158.
3.
Smetana, Karel, et al.. (2023). Technical Note Cell Dysplasia – Cell Dysplastic Features (A Morphological Note). Folia Biologica. 69(1). 34–39.
4.
Březinová, Jana, et al.. (2023). Inhibition of casein kinase 2 induces cell death in tyrosine kinase inhibitor resistant chronic myelogenous leukemia cells. PLoS ONE. 18(5). e0284876–e0284876. 7 indexed citations
5.
6.
Hercog, Rajna, et al.. (2017). Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment. Journal of Experimental & Clinical Cancer Research. 36(1). 55–55. 18 indexed citations
7.
8.
Poláková, Kateřina Machová, Vojtěch Kulvait, Jana Linhartová, et al.. (2014). Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. Journal of Cancer Research and Clinical Oncology. 141(5). 887–899. 57 indexed citations
9.
Smetana, Karel, et al.. (2013). Microscopic notes on the perinucleolar chromatin region in immature and mature human B-leukemia lymphocytes. Neoplasma. 60(3). 284–289. 2 indexed citations
10.
11.
12.
Poláková, Kateřina Machová, Hana Klamová, Pavel Burda, et al.. (2011). Expression patterns of microRNAs associated with CML phases and their disease related targets. Molecular Cancer. 10(1). 41–41. 116 indexed citations
13.
Smetana, Karel, et al.. (2009). A short cytochemical note on the nucleolar and cytoplasmic RNA concentration in differentiating cells represented by human erythroblasts. Acta Histochemica. 112(4). 407–411. 3 indexed citations
14.
15.
Smetana, Karel, et al.. (2006). A Karyometric Note on Nucleoli in Human Early Granulocytic Precursors. Folia Biologica. 52(1-2). 16–20. 1 indexed citations
16.
Merkerová, Michaela Dostálová, Hana Klamová, R Brdička, & Hana Bruchova. (2006). Targeting of gene expression by siRNA in CML primary cells. Molecular Biology Reports. 34(1). 27–33. 27 indexed citations
17.
Zemanová, Zuzana, et al.. (2006). Complex chromosomal rearrangements in patients with chronic myeloid leukemia. Cancer Genetics and Cytogenetics. 168(1). 22–29. 19 indexed citations
18.
Smetana, Karel, et al.. (2005). Intranucleolar Translocation of AgNORs in Early Granulocytic Precursors in Chronic Myeloid Leukaemia and K 562 Cells. Folia Biologica. 51(4). 89–92. 7 indexed citations
19.
Smetana, Karel, et al.. (2005). Nucleoli in Human Early Erythroblasts (K2, K1, K1/2 Cells). Folia Biologica. 51(1). 25–28. 1 indexed citations
20.
Hrkal, Zbyněk, et al.. (2000). [Selective photodynamic destruction of leukemic cells].. PubMed. 139(5). 148–54. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Traudl Henn Breakdown of academic impact, for papers by Jeffrey A. Durocher Breakdown of academic impact, for papers by Yasuhiko Kamikubo Breakdown of academic impact, for papers by Stéphanie Salesse Breakdown of academic impact, for papers by Kazuhiro Maki Breakdown of academic impact, for papers by Haruna Naito Breakdown of academic impact, for papers by Crescenzio Francesco Minervini Breakdown of academic impact, for papers by ID Dube Breakdown of academic impact, for papers by Jeffrey R. Shearstone Breakdown of academic impact, for papers by Elenoe C. Smith
Rankless by CCL
2026